Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1.
作者信息
Gafni Rachel I, Hartley Iris R, Roszko Kelly L, Nemeth Edward F, Pozo Karen A, Lombardi Ed, Sridhar Ananth V, Roberts Mary S, Fox Jonathan C, Collins Michael T
机构信息
National Institutes of Health, Bethesda, MD
MetisMedica, Toronto, ON, Canada.
出版信息
N Engl J Med. 2023 Sep 28;389(13):1245-1247. doi: 10.1056/NEJMc2302708.
Abstract
摘要
相似文献
1
Efficacy and Safety of Encaleret in Autosomal Dominant Hypocalcemia Type 1.恩卡雷肽治疗1型常染色体显性低钙血症的疗效与安全性。
N Engl J Med. 2023 Sep 28;389(13):1245-1247. doi: 10.1056/NEJMc2302708.
2
Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH).钙敏感受体（CaSR）突变基因敲入小鼠模拟常染色体显性低钙血症（ADH）的异常，钙敏调节剂可改善这些异常。
J Bone Miner Res. 2015 Nov;30(11):1980-93. doi: 10.1002/jbmr.2551. Epub 2015 Jul 16.
3
Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPSP795 (SHP635).治疗常染色体显性低钙血症 1 型的钙敏感受体激动剂 NPSP795（SHP635）。
J Bone Miner Res. 2019 Sep;34(9):1609-1618. doi: 10.1002/jbmr.3747. Epub 2019 Jul 26.
4
Activating calcium-sensing receptor gene variants in children: a case study of infant hypocalcaemia and literature review.儿童中激活钙敏感受体基因变异：婴儿低钙血症病例研究及文献综述
Acta Paediatr. 2014 Nov;103(11):1117-25. doi: 10.1111/apa.12743. Epub 2014 Aug 24.
5
Knockin mouse with mutant G mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors.敲除带有突变 G 的小鼠模拟人类遗传性低钙血症，并可被药物抑制剂挽救。
JCI Insight. 2017 Feb 9;2(3):e91079. doi: 10.1172/jci.insight.91079.
6
G mutation in mice causes hypocalcemia rectifiable by calcilytic therapy.G 突变小鼠导致低钙血症，可通过钙敏感受体激动剂治疗纠正。
JCI Insight. 2017 Feb 9;2(3):e91103. doi: 10.1172/jci.insight.91103.
7
Autosomal Dominant Hypocalcemia Type 1: A Systematic Review.常染色体显性低钙血症 1 型：系统评价。
J Bone Miner Res. 2022 Oct;37(10):1926-1935. doi: 10.1002/jbmr.4659. Epub 2022 Aug 22.
8
Extrapyramidal symptoms and advanced calcification of the basal ganglia in a patient with autosomal dominant hypocalcemia.一名常染色体显性低钙血症患者出现锥体外系症状和基底神经节晚期钙化。
Intern Med. 2013;52(18):2077-81. doi: 10.2169/internalmedicine.52.8375.
9
Autosomal dominant hypocalcemia due to a truncation in the C-tail of the calcium-sensing receptor.由于钙敏感受体C末端截短导致的常染色体显性低钙血症。
Mol Cell Endocrinol. 2017 Jan 5;439:187-193. doi: 10.1016/j.mce.2016.08.032. Epub 2016 Aug 22.
10
Novel calcium-sensing receptor cytoplasmic tail deletion mutation causing autosomal dominant hypocalcemia: molecular and clinical study.导致常染色体显性低钙血症的新型钙敏感受体胞质尾缺失突变：分子与临床研究
Eur J Endocrinol. 2016 Apr;174(4):K1-K11. doi: 10.1530/EJE-15-1216. Epub 2016 Jan 13.
引用本文的文献
1
The cellular effect of intermittent PTH treatment on bone remodeling and modeling in humans-a histomorphometry centered scoping review.间歇性甲状旁腺激素治疗对人体骨重塑和骨建模的细胞效应——一项以组织形态计量学为核心的综述
Osteoporos Int. 2025 Sep 9. doi: 10.1007/s00198-025-07612-z.
2
A calcium-sensing receptor allelic series and underdiagnosis of genetically driven hypocalcemia.钙敏感受体等位基因系列与遗传驱动性低钙血症的诊断不足
Am J Hum Genet. 2025 Aug 7;112(8):1818-1832. doi: 10.1016/j.ajhg.2025.06.013. Epub 2025 Jul 14.
3
2024 FDA TIDES (Peptides and Oligonucleotides) Harvest.2024年美国食品药品监督管理局潮汐计划（肽与寡核苷酸）成果
Pharmaceuticals (Basel). 2025 Feb 20;18(3):291. doi: 10.3390/ph18030291.
4
Characterization of quinazolinone calcilytic therapy for autosomal dominant hypocalcemia type 1 (ADH1).喹唑啉酮类钙敏感受体拮抗剂治疗1型常染色体显性低钙血症（ADH1）的特性研究
J Biol Chem. 2025 Apr;301(4):108404. doi: 10.1016/j.jbc.2025.108404. Epub 2025 Mar 12.
5
Hypoparathyroidism: diagnosis, management and emerging therapies.甲状旁腺功能减退症：诊断、管理及新出现的治疗方法。
Nat Rev Endocrinol. 2025 Jun;21(6):360-374. doi: 10.1038/s41574-024-01075-8. Epub 2025 Feb 4.
6
Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations.1型常染色体显性低钙血症的管理：文献综述与临床实践建议
J Endocrinol Invest. 2025 Apr;48(4):831-844. doi: 10.1007/s40618-024-02496-y. Epub 2024 Nov 28.
7
Hypoparathyroidism: an update on new therapeutic approaches.甲状旁腺功能减退症：新治疗方法的最新进展
Endocrine. 2025 Feb;87(2):420-429. doi: 10.1007/s12020-024-04057-y. Epub 2024 Oct 13.
8
Potential of Calcilytics as a Novel Treatment for Post-Surgical Hypoparathyroidism.钙敏感受体激动剂作为术后甲状旁腺功能减退症新型治疗方法的潜力
Endocrinol Metab (Seoul). 2024 Jun;39(3):534-536. doi: 10.3803/EnM.2024.2035. Epub 2024 May 27.
9
Rare genetic disorders that impair parathyroid hormone synthesis, secretion, or bioactivity provide insights into the diagnostic utility of different parathyroid hormone assays.罕见的遗传性疾病会损害甲状旁腺激素的合成、分泌或生物活性，这为不同甲状旁腺激素检测方法的诊断效用提供了深入的见解。
Curr Opin Nephrol Hypertens. 2024 Jul 1;33(4):375-382. doi: 10.1097/MNH.0000000000000999. Epub 2024 May 3.
10
Treatment of Hypoparathyroidism by Re-Establishing the Effects of Parathyroid Hormone.甲状旁腺激素作用的重建治疗甲状旁腺功能减退症。
Endocrinol Metab (Seoul). 2024 Apr;39(2):262-266. doi: 10.3803/EnM.2024.1916. Epub 2024 Apr 4.
本文引用的文献
1
Autosomal Dominant Hypocalcemia Type 1: A Systematic Review.常染色体显性低钙血症 1 型：系统评价。
J Bone Miner Res. 2022 Oct;37(10):1926-1935. doi: 10.1002/jbmr.4659. Epub 2022 Aug 22.
2
Treatment of Autosomal Dominant Hypocalcemia Type 1 With the Calcilytic NPSP795 (SHP635).治疗常染色体显性低钙血症 1 型的钙敏感受体激动剂 NPSP795（SHP635）。
J Bone Miner Res. 2019 Sep;34(9):1609-1618. doi: 10.1002/jbmr.3747. Epub 2019 Jul 26.
3
Calcilytic Ameliorates Abnormalities of Mutant Calcium-Sensing Receptor (CaSR) Knock-In Mice Mimicking Autosomal Dominant Hypocalcemia (ADH).钙敏感受体（CaSR）突变基因敲入小鼠模拟常染色体显性低钙血症（ADH）的异常，钙敏调节剂可改善这些异常。
J Bone Miner Res. 2015 Nov;30(11):1980-93. doi: 10.1002/jbmr.2551. Epub 2015 Jul 16.
4
Autosomal dominant hypocalcaemia caused by a Ca(2+)-sensing receptor gene mutation.由钙敏感受体基因突变引起的常染色体显性低钙血症
Nat Genet. 1994 Nov;8(3):303-7. doi: 10.1038/ng1194-303.
5
Calcium-ion-sensing cell-surface receptors.钙离子感应细胞表面受体
N Engl J Med. 1995 Jul 27;333(4):234-40. doi: 10.1056/NEJM199507273330407.
Zotero 插件